Postoperative fibrinolytic shutdown has been attributed to an increase in plasma levels of type I plasminogen activator inhibitor (PAI-I) activity and may contribute t o postoperative venous thrombosis. The purpose of this study was to determine whether the postoperative increase in PAL1 is contributed t o by a plasma mediator(s) that stimulates PAL1 synthesis and secretion by vascular endothelium. Plasma samples collected from patients (N = 11) before and after surgery for total hip replacement were (1) assayed for endogenous plasma PAL1 antigen and activity, and (2) incubated with cultured human umbilical vein endothelial cells (HUVECs) and PAL1 antigen and activity measured in the conditioned medium (CM). Eighteen hours after surgery, endogenous plasma levels of PAL1 antigen and activity were increased by 225% (P = .003) and 190% (P = .04), respectively over the preoperative values. In addition, compared with preoperative plasma, postoperative plasma increased HUVEC secretion of PAL1 antigen and activity by 99% (P = .OOl) and 66%
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ATIENTS WHO HAVE major surgery are at risk of P developing venous thrombosis and pulmonary embolism.' A number of factor(s) are thought to contribute to the risk of postoperative venous thrombosis. These include increased blood coagulability, stasis, and impaired fibrinolytic activity.2 Reduced fibrinolytic activity is a wellrecognized feature of the early postoperative state and has been referred to as fibrinolytic s h~t d o w n .~
A number of studies have demonstrated an association between the extent of reduction in fibrinolytic activity on the first day postoperatively and the occurrence of postoperative thromb o~i s .~-'~ Recent evidence indicates plasma levels of type 1 plasminogen activator inhibitor (PAI-1) are increased postoperatively and this fibrinolytic inhibitor is thought to be a major contributor to the fibrinolytic shutdown phenome-PAI-1 is synthesized and secreted by endothelial cells and other vascular wall c e l l~.~~J~ Recent studies in vitro and in vivo have demonstrated that PAI-1 synthesis is stimulated by a number of inflammatory mediators such as tumor n~n .~-~~ necrosis factor (TNF), interleukin-1 (IL-l), and bacterial lipopolysaccharide (LPS),'6-22 but their respective role, if any, in the mechanism of postoperative increase of plasma PAI-1 levels has not been elucidated.
In the present study we used cultured human umbilical vein endothelial cells (HUVECs) to determine whether soluble mediator(s) contribute to the postoperative increase in plasma PAI-1 activity. We confirmed the observation that postoperative fibrinolytic shutdown is associated with an increase in plasma levels of PAI-1 and made the new observation that postoperative plasma obtained from patients who had undergone elective hip replacement surgery contains factor(s) that stimulate endothelial cell PAI-1 biosynthesis and secretion. rabbit polyclonal antihuman TNFa, and antihuman IL-la IgG (Endogen Inc, Boston, MA).
Blood samples were obtained from patients who had undergone total hip replacement surgery. Heparinized and citrated blood was collected preoperatively and 3, 8, 18, and 42 hours postoperatively. All patients received prophylactic heparin starting after the 18-hours postoperative blood sample was drawn. Platelet-poor plasma was prepared by double centrifugation of blood at 3, OOOg at 4°C for 15 minutes. Aliquots were kept at -70°C until assayed. Heat-treated plasma was prepared by incubating samples in a water bath maintained at 56°C for 30 minutes.
HUVECs were isolated by collagenase digestion from umbilical cord segments as described," and grown in primary culture on 25-cm2 tissue culture flasks using M199 containing 20% fetal calf serum (FCS), endothelial cell growth factor (20 pgimL), porcine intestinal heparin (90 pgimL), penicillin (100 U/mL), and streptomycin (100 pg/mL). Before each experiment, confluent second-or third-passage HUVECs in 24-well tissue culture plates were washed with phosphate-buffered saline (PBS) and then incubated for up to 16 hours with 5% heparinized patient plasma in M199. The conditioned medium (CM) was collected from duplicate wells, centrifuged at 2, OOOg for 5 minutes to remove cell debris, and frozen at -70°C until assayed. For metabolic radiolabeling experiments, HUVECs in 60" dishes were incubated for 6 hours with 3 mL of methionine-free Dulbecco's media containing 100 pCiimL 35S-methionine and 2.5% heparinized patient or normal pooled plasma (NPP). CM was centrifuged and aliquots stored at -70°C until assayed.
Immunoprecipitation of radiolabeled PAI-1 was performed as d e s~r i b e d .~~ Briefly, 500 pLof CM samples were precleared with normal rabbit IgG and protein-A-Sepharose (1:lO wt/vol; 50 pL) for 2 hours at 4°C. After centrifuging at 2,000g for 5 minutes, the supernatants were incubated overnight at 4°C with either normal rabbit IgG or rabbit antihuman PAL1 IgG. The IgG fraction was isolated from rabbit serum by caprylic acid precipitation as described.26 The IgG complexes were precipitated with protein-A-Sepharose (1:lO wti vol), the beads washed twice with washing buffer (0.01 mol/L Tris-HC1 pH 8.0 containing 0.14 mol/L NaCI, 0.5% Triton X-100, 1 mmoliL PMSF, 5 mmol/L iodoacetamide, 0.2 UimL aprotinin) and then once with washing buffer containing 0.1% sodium dodecyl sulfate (SDS). The beads were suspended in 30 pL of Laemmli sample buffer (2% SDS, 10% glycerol, 0.5 mg/mL bromophenol blue, 0.125 moliL Tris-HCL pH 6.8 and 1% P-mercaptoethanol), boiled, and then fractionated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using 4% stacking and 9% separating gels (20"C, 16 hours, 50 V). Gels were treated with Amplify for 1 hour, dried under vacuum at 80°C, and exposed to Kodak XAR5 film (Eastman Kodak, Rochester, NY). The bands corresponding to purified PAI-1 were cut out of the dried gels and quantitated by P-counting. Trichloroacetic acid (TCA) precipitation of total Plasma preparation.
Cell culture. 35S-methionine incorporation into biosynthetically radiolabeled proteins was determined in the CM and Triton X-100 soluble cell extracts as des~ribed.~' PAI-1 activiiy assay. Active PAI-1 antigen was determined in the citrated plasma and HUVEC CM by a immunoradiometric assay as previously Briefly, 96-well polystyrene microtiter plates were coated overnight at 4°C with purified recombinant t-PA in PBS (50 pL/well; 5 pg/mL). Nonspecific protein binding sites were blocked with blocking buffer (PBS containing 3% BSA, 0.05% Tween-20, and 0.02% NaN3). The wells were washed with SPRIA buffer (PBS containing 0.1% BSA, 0.05% Tween-20, and 0.05% NaN3), and then incubated for 2 hours at 37°C with samples diluted in IRMAbuffer (PBS containing 3% BSA, 0.1% Tween-80, aprotinin 20 UlmL, 5 mmol/L EDTA, and 0.05% NaN3). After washing, the bound PAI-1 was detected by incubating the wells for 1 hour at 37°C with rabbit antihuman PAL1 IgG (1 pg/mL in IRMA buffer) followed by incubation for 1 hour at 37°C with lZ51-goat antirabbit IgG (5 x lo4 cpmiwell). The washed wells were cut out and the bound radioactivity determined by y-counting. Results are expressed relative to a human recombinant human PAI-1 standard (DuPont-Merck Pharmaceuti~al)~~ diluted in PAIl-depleted normal citrated human plasma in which 1 U activity corresponds to 10 ng of antigen as determined by titration with t-PA using the Spectrolyse assay (Biopool, Inter-Haematol Inc, Hamilton, Ontario, Canada).
Quantitation of radiolabeled H w E C s PAI-1.
Total PAI-1 antigen in citratod plasma and HUVEC CM was determined by a competitive radioimmunoassay as previously described.29 Briefly, 96-well polystyrene microtiter plates were coated overnight at 4°C with PAL1 diluted in PBS (300 ng/mL, 50 pL/well). Nonspecific protein binding sites were blocked with blocking buffer. After washing, the wells were incubated for 2 hours at 37°C with samples that were preincubated overnight with rabbit antihuman PAL1 IgG in IRMA buffer (1 pgimL final dilution). After washing, the bound anti-PAI-1 IgG was detected by incubating wells for 1 hour at 37°C with lZI-goat antirabbit IgG (5 x 10" cpmiwell). The washed wells were cut out and the bound radioactivity determined by y-counting.
TNFa and IL-la antigen levels were determined in citrated plasma by ELISA according to the manufacturer's instructions. For antibody neutralization experiments, HUVECs were incubated for 6 hours with 5% preoperative or postoperative plasma containing rabbit antihuman TNFa, anti-IL-la, or preimmune IgG fraction (1 to 10 pgimL). Controls included HUVECs incubated with patient plasma containing TNFa (5 UimL) or IL-la (2.5 UlmL) in the presence or absence of neutralizing or preimmune rabbit IgG. CM samples were collected and analyzed for PAI-1 antigen as described above.
HUVECs in 25-cm2 tissue culture flasks were incubated for 6 hours with 5% preoperative or postoperative heparinized plasma and the total RNA isolated by acid guanidium isothiocyanate-phenol-chloroform method as d e~c r i b e d .~~
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RESULTS
Time course ofplasma PAI-1 activity and antigen in relation to surgev. Levels of plasma PAI-1 antigen and activity measured in two patients preoperatively and postoperatively are shown in Fig 1. Peak levels for both PAI-1 antigen (Fig 1A) and activity (Fig 1B) were observed at 18 hours postoperatively. We then determined the preoperative and 18 hours postoperative plasma PAI-1 antigen and activity in 11 patients who had undergone elective hip replacement surgery ( Table 1 ). The mean increment of PAI-1 antigen and activity in postoperative plasma was 225% (P = .003) and 190% (P = .04), respectively ( Table 2 ). To establish whether the obsetvcd increase in plasma PAL1 was a result of secretion or synthesis of PAI-1 by endothelial cells in response to a circulating factor(s), HUVECs were incubated with various doscs preoperative and postoperative plasma and PAI-1 lcvcls determined in the CM. The incubation of HUVECs with 18-hour postoperative plasma resulted in a dose-dependent (Fig 2) increase in PAI-1 antigen and activity in the CM by 99% (P = .001) and 66% (P = .002), respectively ( Table 2 ). HUVECs were incubated overnight (16 hours) with 5% preoperative or postoperative (18 hours) patient plasma (N = 11) and the PAI-1 antigen and activity in the CM was analyzed as described in Materials and Methods.
Metabolic radiolabeling and immunoprecipiration of HU-

VECPAI-1.
To establish whether the increase of PAI-I in HUVEC CM was caused by de novo biosynthesis, HUVECs were metabolically radiolabeled with 3%-mcthioninc for 6 hours in the presence of preoperative or postoperative plasma from various patients and the resulting 3SS-labeled PAL1 was collectcd by immunoprecipitation and quantitated (Fig 3) . Postoperative plasmas increased the amount of W l a b e l e d PAL1 in the CM by an average of 40% (Fig 3,  lanes 2 and 4) relative to preoperative plasmas (Fig 3, lanes   1 and 3) . This increase in 3sS-labeled PAL1 was relatively specific because total incorporation of 3sS-methionine into TCA precipitable protcin was decreased to approximately 90% of preoperative plasma-trcated cells. Treatment of HUVECs with NPP in the presence or absence of LPS (10 &mL) resulted in a 70% relative increase in 3sS-labcled HUVECs were incubated for 6 hours with preoperative or postoperative plasmas and the total R N A isolated and analyzed for PAI-1 mRNA as described in Materials and Methods. The 18-hour postoperative plasma induced a 5.1-fold (Fig 4, lane 2, patient A) 
PAI-1.
Northem blot analysis. (Fig 4, lanes 1  and 4, patients A and B, respectivcly) as dctcrmined by scanning dcnsitomctry. Similarly, 42-hour postopcrativc plasma induccd a 2.7-fold incrcasc in the 3.2-kb and a 1.3-fold incrcasc in the 2.3-kb PAI-1 mRNA exprcssion (Fig 4, lanc 3 ). This incrcasc in HUVEC PAL1 mRNA exprcssion by postopcrative plasma was comparablc with that induced by purified LPS (Fig 4, lane 6) .
Identification of the soliible mediator(s). Experiments werc pcrformed to dctcrmine thc identity of the soluble mediator(s) in postoperativc plasma. Our findings failcd to confirm a dircct rolc for TNFa or IL-la in thc stimulation of HUVEC PAL1 biosynthesis. Plasma antigcn lcvels of TNFa and IL-la werc not clcvatcd 18 hours or 42 hours postoperativcly in the scvcn paticnts analyzcd (Table 3) . Howcvcr, the incubation of HUVECs with cithcr TNFa (5 U/mL) or IL-la (2.5 U/mL) rcsultcd in an increasc in PAL1 antigen in the CM that was inhibited by specific antibodies to these cytokines (Fig 5) . Moreover of HUVECs with preoperative or postopcrative patient plasma containing neutralizing antibodies to TNFa or IL-la had no cffcct on sccretion of PAL1 into the CM ( Fig  5, A and B) . Thc prcoperative and postoperativc plasma samples wcrc subjected to diffcrcntial ccntrifugal ultrafiltration and the cffccts of the rctcntates and filtratcs on HUVEC PAI-1 antigcn sccretion werc examined. Stimulation of HUVEC PAI-1 biosynthcsis by postoperative plasma filtratcs was only detccted after ultrafiltration using 100-Kd MW-cutoff mcmbrancs (Fig  6B) . In contrast, stimulation of HUVEC PAL1 biosynthesis by postoperativc plasma was retained only by the 10-and 30-Kd MW-cutoff membranes (Fig 6C) . Furthermorc, treatment of postopcrativc plasma at 56°C for 30 minutcs abolishcd the induction of HUVEC PAI-I production (data not shown).
Characterization of the soluble mediator(s).
DISCUSSION
In this study, we used cultured HUVECs incubated with prcopcrative or postoperativc plasma to explore the mecha- Preoperative and postoperative patients plasmas (N = 7) were analyzed for TNFa and IL-la antigen by specific ELlSAs as described in Materials and Methods.
nism of the postoperative increase in PAI-1 levels. First, we confirmed the previous observation of an increase in plasma PAI-1 activity and antigen post~peratively.~-~~~~-~~ Peak levels appear approximately 18 hours after surgery (Fig 1,  Table 2 ). Secondly, our results from the metabolically radiolabeled immunoprecipitation of PAI-1 (Fig 3) and Northern blot analysis of PAI-1 mRNA expression (Fig 4) confirmed the presence of soluble factors in postoperative plasma that stimulate de novo biosynthesis of PAI-1 by HUVECs. This increase in HUVEC PAI-1 biosynthesis was substantial and comparable with that induced by purified LPS (Fig 4) , TNFa, or IL-la (Fig 5) . (Table 3) , nor do they contribute to the observed functional HUVEC stimulatory activity in preoperative or postoperative plasma (Fig 5) . There has been one report of an elevation of IL-1 after cardiopulmonary bypass surgery,44 but an effect of other surgical procedures on the plasma levels of this cytokine has not been reported. In addition, a recent study has demonstrated no significant increase in TNF levels in patients undergoing partial pan~reatectomy.~~ Thrombin generated during blood coagulation is an unlikely candidate for the postoperative plasma stimulating activity because we used heparinized patient plasma that does not express free factor IIa activity. Lp(a) alters fibrinolysis by competing with plasminogen for binding to endothelial cells46 and by inducing the synthesis of PAI-l.40 Plasma levels Lp(a) have been reported to be elevated in the postoperative period4' and in patients with cancer or postmyocardial i n f a r~t i o n .~~.~~-~* However, Lp(a) is unlikely to be responsible for our observed stimulating activity because its molecular weight is greater than lo6 daltons and our ultrafiltration experiments indicate that the molecular weight of the postoperative plasma mediator(s) is between approximately 30 and 100 Kd (Fig 6) . Postoperative plasma levels of IL-6, the major regulator of the acute phase were elevated over preoperative levels in six of eight patients analyzed (data not shown). Similar data were reported post-partial pancreate~tomy.~~ However, recent in vivo3* and in vitro studies with cultured H U V E C S *~,~~ indicate that PAI-1 synthesis is unresponsive to IL-6. The possible role of TGF-P in the postoperative plasma stimulation of endothelial cell PAI-1 synthesis is currently being investigated.
Perturbation of human and bovine endothelial cells in culture results in an increased synthesis16-1y*z1~22 and cell surface expressionz0 of PAI-1, tissue f a~t o r~~,~~ and a decreased synthesis and cell surface expression of thrombom o d~l i n .~~ In addition, perturbed endothelial cells synthesize and secrete IL-653 and IL-1,54 which may further amplify the local and systemic prothrombotic response to trauma. Therefore, it is possible that the mediator(s) in postoperative plasma that we have shown to stimulate HUVEC PAI-1 synthesis also upregulates the endothelial cell surface expression of tissue factor as well as downregulating thrombomodulin. It is also possible that these endothelia1 changes are of major importance in the pathogenesis of Postoperative venous thrombosis and other clinical conditions that predispose to venous thrombosis. The identity and functional characterization of the soluble postoperative plasma mediator(s) that induced PAI-1 synthesis remains to be elucidated.
